|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.49 USD | +23.76% |
|
+17.51% | -41.38% |
Scinai Immunotherapeutics Ltd. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 6.5 million compared to USD 5.8 million a year ago. Basic loss per share from continuing operations was USD 16 compared to USD 40 a year ago.
Diluted loss per share from continuing operations was USD 16 compared to USD 40 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -41.38% | 1.62M | |
| +40.80% | 53.67B | |
| +36.53% | 38.86B | |
| -8.05% | 38.76B | |
| -8.98% | 27.27B | |
| +10.69% | 25.91B | |
| -16.21% | 20.29B | |
| +31.00% | 12.78B | |
| +28.51% | 12.18B | |
| -1.67% | 11.96B |
SCINAI IMMUNOTHERAPEUTICS LTD. 
